Updated LibtayoŽ (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma

Thursday, May 16, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Regeneron Contacts:

Sanofi Contacts:

 

Media Relations

Daren Kwok

Tel: +1 (914) 847-1328

daren.kwok@regeneron.com

 

Investor Relations

Mark Hudson

Tel: +1 (914) 847-3482

Mark.Hudson@regeneron.com 

 

Media Relations

Ashleigh Koss

Tel: +1 (908) 981-8745

ashleigh.koss@sanofi.com

 

Investor Relations

George Grofik

Tel.: +33 (0)1 53 77 45 45

ir@sanofi.com 



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store